ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,555.74
-0.16%
US Tech 100
19,095.20
-1.09%
Dow Jones
40,358.09
-0.14%
Brent Oil
80.475
-0.37%
Bitcoin
65,820.35
-0.16%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. BridgeBio Pharma Inc (BBIO)

  7. BridgeBio Pharma Inc (BBIO) News

BBIO

BridgeBio Pharma (BBIO)

BridgeBio Pharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BBIO
DateTimeSourceHeadlineSymbolCompany
07/23/20244:12PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BBIOBridgeBio Pharma Inc
07/23/20247:30AMGlobeNewswire Inc.BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating OfficerNASDAQ:BBIOBridgeBio Pharma Inc
07/05/20244:31PMGlobeNewswire Inc.BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BBIOBridgeBio Pharma Inc
06/18/20247:30AMGlobeNewswire Inc.BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)NASDAQ:BBIOBridgeBio Pharma Inc
06/10/20247:30AMGlobeNewswire Inc.BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BBIOBridgeBio Pharma Inc
06/06/20247:30AMGlobeNewswire Inc.BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare ConferenceNASDAQ:BBIOBridgeBio Pharma Inc
06/06/20246:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BBIOBridgeBio Pharma Inc
06/04/20247:30AMGlobeNewswire Inc.BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for HypochondroplasiaNASDAQ:BBIOBridgeBio Pharma Inc
06/03/20244:01PMGlobeNewswire Inc.BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024NASDAQ:BBIOBridgeBio Pharma Inc
05/29/20244:01PMGlobeNewswire Inc.Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)NASDAQ:BBIOBridgeBio Pharma Inc
05/24/20247:30AMGlobeNewswire Inc.BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA MeetingNASDAQ:BBIOBridgeBio Pharma Inc
05/17/20244:09PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
05/15/20247:30AMGlobeNewswire Inc.BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BBIOBridgeBio Pharma Inc
05/14/20247:30AMGlobeNewswire Inc.BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024NASDAQ:BBIOBridgeBio Pharma Inc
05/13/20247:30AMGlobeNewswire Inc.BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified SensitiNASDAQ:BBIOBridgeBio Pharma Inc
05/02/20247:30AMGlobeNewswire Inc.BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business UpdateNASDAQ:BBIOBridgeBio Pharma Inc
05/02/20247:00AMGlobeNewswire Inc.BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipelineNASDAQ:BBIOBridgeBio Pharma Inc
04/10/20247:30AMGlobeNewswire Inc.BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BBIOBridgeBio Pharma Inc
04/07/20241:15PMGlobeNewswire Inc.BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)NASDAQ:BBIOBridgeBio Pharma Inc
03/20/20247:30AMGlobeNewswire Inc.BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BBIOBridgeBio Pharma Inc
03/06/20245:15PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BBIOBridgeBio Pharma Inc
03/06/20245:13PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BBIOBridgeBio Pharma Inc
03/05/202411:53PMGlobeNewswire Inc.BridgeBio Pharma Announces Pricing of Public Offering of Common StockNASDAQ:BBIOBridgeBio Pharma Inc
03/04/20245:25PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BBIOBridgeBio Pharma Inc
03/04/20244:17PMGlobeNewswire Inc.BridgeBio Pharma Announces Proposed Public Offering of Common StockNASDAQ:BBIOBridgeBio Pharma Inc
03/04/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BBIOBridgeBio Pharma Inc
03/04/20242:30AMGlobeNewswire Inc.BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CMNASDAQ:BBIOBridgeBio Pharma Inc
02/22/20244:27PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:BBIOBridgeBio Pharma Inc
02/22/20247:31AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BBIOBridgeBio Pharma Inc
02/22/20247:30AMGlobeNewswire Inc.BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdateNASDAQ:BBIOBridgeBio Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:BBIO

Your Recent History

USOTC
NWPN
Now (PK)
USOTC
KEGS
1812 Brewing (PK)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
RONN
Ronn Motor (PK)
USOTC
ITUP
Interups (CE)
USOTC
ENZC
Enzolytics (PK)
USOTC
AABB
Asia Broadband (PK)
NASDAQ
TSLA
Tesla
NYSE
AMC
AMC Entertainment
NASDAQ
NB
NioCorp Developments
USOTC
IDVV
International Endeavors (PK)
USOTC
ECSL
Ecare Solutions (PK)
USOTC
SPZI
Spooz (PK)
NASDAQ
COOP
Mr Cooper
USOTC
SMCE
SMC Entertainment (PK)
USOTC
GDVM
Global Developments (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved